US 11,939,360 B2
Pharmaceutical composition for preventing or treating inflammatory diseases including Toxoplasma gondii GRA9 protein or gene encoding the protein as active ingredient
Chul-Su Yang, Gyeonggi-do (KR); and Jae-Sung Kim, Gyeonggi-do (KR)
Assigned to INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS, Ansan-si (KR)
Filed by INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS, Gyeonggi-do (KR)
Filed on Feb. 28, 2022, as Appl. No. 17/682,544.
Claims priority of application No. 10-2021-0033920 (KR), filed on Mar. 16, 2021.
Prior Publication US 2022/0306707 A1, Sep. 29, 2022
Int. Cl. A61P 31/04 (2006.01); A23L 33/00 (2016.01); A23L 33/195 (2016.01); A61K 38/00 (2006.01); A61P 37/06 (2006.01); C07K 14/45 (2006.01)
CPC C07K 14/45 (2013.01) [A23L 33/195 (2016.08); A23L 33/40 (2016.08); A61P 31/04 (2018.01); A61P 37/06 (2018.01); A23V 2002/00 (2013.01); A61K 38/00 (2013.01)] 6 Claims
 
1. A method for treating an inflammatory disease, the method comprising a step of administering to an individual a composition including Toxoplasma gondii GRA9 protein as an active ingredient.